A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity

Richmond, 2003, Lassa fever: epidemiology, clinical features, and social consequences, BMJ, 327, 1271, 10.1136/bmj.327.7426.1271 Anonymous, 2005, Update on Lassa fever in West Africa, Weekly Epidemiol Rec, 80, 86 Macher, 2006, Historical Lassa fevers reports and 30-year clinical update, Emerg Infect Dis, 12, 835, 10.3201/eid1205.050052 Borio, 2002, Hemorrhagic fever viruses as biological weapons: medical and public health management, JAMA, 287, 2391, 10.1001/jama.287.18.2391 McCormick, 1992, Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys, J Med Virol, 31, 1, 10.1002/jmv.1890370102 McCormick, 1986, Lassa fever. Effective therapy with ribavirin, N Engl J Med, 314, 20, 10.1056/NEJM198601023140104 Fisher-Hoch, 2001, Towards a human Lassa fever vaccine, Rev Med Virol, 11, 331, 10.1002/rmv.329 Fisher-Hoch, 2004, Lassa fever vaccine, Expert Rev Vaccines, 3, 103, 10.1586/14760584.3.2.189 Monath, 2004, Yellow fever vaccine, 1095 Lukashevich, 1992, Generation of reassortants between African arenaviruses, Virology, 188, 600, 10.1016/0042-6822(92)90514-P Lukashevich, 2005, A live-attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses, J Virol, 79, 13934, 10.1128/JVI.79.22.13934-13942.2005 Moshkoff, 2007, Molecular characterization of a reassortant virus derived from Lassa and Mopeia viruses, Virus Genes, 34, 169, 10.1007/s11262-006-0050-3 Lukashevich, 1984, Ribonucleic acids of Machupo and Lassa viruses, Arch Virol, 79, 189, 10.1007/BF01310811 Lukashevich, 2006, Lassa virus genome, Curr Genomics, 7, 351, 10.2174/138920206778948673 Lukashevich, 1997, The Lassa fever virus L gene: nucleotide sequence, comparison, and precipitation of a predicted 250kDa protein with monospecific antiserum, J Gen Virol, 78, 547, 10.1099/0022-1317-78-3-547 Djavani, 1997, Completion of the Lassa fever virus sequence and identification of a RING finger open reading frame at the L RNA 5′ end, Virology, 235, 414, 10.1006/viro.1997.8722 Auperin, 1986, Nucleotide sequence of the glycoprotein gene and intergenic region of the Lassa virus S genome RNA, Virology, 154, 155, 10.1016/0042-6822(86)90438-1 Clegg, 1991, Nucleotide sequence of the S RNA of Lassa virus (Nigerian strain) and comparative analysis of arenavirus gene products, Virus Res, 18, 151, 10.1016/0168-1702(91)90015-N Lenz, 2001, The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P, PNAS, 98, 12701, 10.1073/pnas.221447598 Riviere, 1985, Genetic mapping of lymphocytic choriomeningitis virus pathogenicity: virulence in guinea pigs is associated with the L RNA segment, J Virol, 55, 704, 10.1128/JVI.55.3.704-709.1985 Emonet, 2006, Phylogeny and evolution of old world arenaviruses, Virology, 350, 251, 10.1016/j.virol.2006.01.026 Charrel, 2003, New insights into the evolutionary relationships between arenaviruses provided by comparative analysis of small and large segment sequences, Virology, 317, 191, 10.1016/j.virol.2003.08.016 Archer, 2002, High genetic divergence and recombination in Arenaviruses from the Americas, Virology, 304, 274, 10.1006/viro.2002.1695 Zhang, 2001, Reassortant analysis of guinea pig virulence of Pichinde virus variants, Virology, 290, 30, 10.1006/viro.2001.1127 Gerrard, 2004, Ngari virus is a bunyamwera virus reassortant that can be associated with large outbreaks of hemorrhagic fever in Africa, J Virol, 78, 8922, 10.1128/JVI.78.16.8922-8926.2004 Sall, 1999, Genetic reassortment of Rift Valley fever virus in nature, J Virol, 73, 8196, 10.1128/JVI.73.10.8196-8200.1999 Hewson, 2004, Evidence of segment reassortment in Crimean-Congo haemorrhagic fever virus, J Gen Virol, 85, 3059, 10.1099/vir.0.80121-0 Bowen, 2000, Genetic diversity among Lassa virus strains, J Virol, 74, 6992, 10.1128/JVI.74.15.6992-7004.2000 Gunther, 2000, Imported Lassa fever in Germany: molecular characterization of a new Lassa virus strain, Emerg Infect Dis, 6, 466, 10.3201/eid0605.000504 Saluzzo, 1990, Use of reassortant viruses to map attenuating and temperature-sensitive mutations of the Rift Valley fever virus MP-12 vaccine, Vaccine, 8, 369, 10.1016/0264-410X(90)90096-5 Le Nouën, 2006, Very virulent infectious bursal disease virus: reduced pathogenicity in a rare natural segment-B-reassorted isolate, J Gen Virol, 87, 209, 10.1099/vir.0.81184-0 Peters, 1987, Experimental studies of arenaviral hemorrhagic fevers, Curr Top Microbiol Immunol, 134, 5 Pushko, 2001, Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses, J Virol, 75, 11677, 10.1128/JVI.75.23.11677-11685.2001 Demby, 1994, Early diagnosis of Lassa fever by reverse transcription-PCR, J Clin Microbiol, 32, 2898, 10.1128/JCM.32.12.2898-2903.1994 Lukashevich, 2004, LCMV-mediated hepatitis in rhesus macaques: WE but not ARM strain activates hepatocytes and induces liver regeneration, Arch Virol, 149, 2319, 10.1007/s00705-004-0385-9 Lukashevich, 1993, Lassa virus activity in Guinea: distribution of human antiviral antibody defined using enzyme-linked immunosorbent assay with recombinant antigen, J Med Virol, 40, 210, 10.1002/jmv.1890400308 Jasenosky, 2001, Ebola virus VP40-induced particle formation and association with lipid bilayer, J Virol, 75, 5205, 10.1128/JVI.75.11.5205-5214.2001 Bredenbeek, 2006, A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins, Virology, 345, 299, 10.1016/j.virol.2005.12.001 Jahrling, 1982, Pathogenesis of Lassa virus infection in guinea pigs, Infect Immun, 37, 771, 10.1128/IAI.37.2.771-778.1982 Lukashevich, 1986, Some biochemical properties of Lassa virus RNA and polypeptides, Med Microbiol Immunol (Berl), 175, 73, 10.1007/BF02122419 Lukashevich, 1985, Sedimentation analysis of the RNAs isolated from interfering particles of Lassa and Machupo viruses, Acta Virol, 29, 455 Asper, 2004, Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus, J Virol, 78, 3162, 10.1128/JVI.78.6.3162-3169.2004 McCormick, 2002, Lassa fever, Curr Top Microbiol Immunol, 262, 75 Lozano, 1997, Characterization of arenaviruses using a family-specific primer set for RT-PCR amplification and RFLP analysis. Its potential use for detection of uncharacterized arenaviruses, Virus Res, 49, 79, 10.1016/S0168-1702(97)01458-5 Bowen, 1997, Phylogenetic analysis of the Arenaviridae: patterns of virus evolution and evidence for cospeciation between arenaviruses and their rodent hosts, Mol Phylogenet Evol, 8, 301, 10.1006/mpev.1997.0436 Clegg, 2002, Molecular phylogeny of the Arenaviridae, Curr Top Microbiol Immunol, 262, 1 Whitton, 1989, Molecular analyses of a five-amino-acid cytotoxic T-lymphocyte (CTL) epitope: an immunodominant region which induces nonreciprocal CTL cross-reactivity, J Virol, 63, 4303, 10.1128/JVI.63.10.4303-4310.1989 Schulz, 1991, Major histocompatibility complex binding and T cell recognition of a viral nonapeptide containing a minimal tetrapeptide, Eur J Immunol, 21, 1181, 10.1002/eji.1830210513 Djavani, 2000, Murine immune responses to mucosally delivered Salmonella expressing Lassa fever virus nucleoprotein, Vaccine, 18, 1543, 10.1016/S0264-410X(99)00439-9 Djavani, 2001, Mucosal immunization with Salmonella typhimurium expressing Lassa virus nucleocapsid protein cross-protects mice from lethal challenge with lymphocytic choriomeningitis virus, J Hum Virol, 4, 103 Rodriguez-Carreno, 2005, Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein, Virology, 335, 87, 10.1016/j.virol.2005.01.019 La Posta, 1993, Cross-protection against lymphocytic choriomeningitis virus mediated by a CD4+ T cell clone specific for an envelope glycoprotein epitope of Lassa virus, J Virol, 67, 3497, 10.1128/JVI.67.6.3497-3506.1993 Glushakova, 1990, Prediction of arenavirus fusion peptides on the basis of computer analysis of envelope protein sequences, FEBS Lett, 269, 145, 10.1016/0014-5793(90)81140-J Meulen, 2004, Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T cell clones, Virology, 321, 134, 10.1016/j.virol.2003.12.013 Clegg, 1987, Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guinea pigs against Lassa fever, Lancet, 2, 186, 10.1016/S0140-6736(87)90767-7 Fisher-Hoch, 2000, Effective vaccine for Lassa fever, J Virol, 74, 6777, 10.1128/JVI.74.15.6777-6783.2000 ter Meulen, 2000, Characterization of human CD4+ T cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein, J Virol, 74, 2186, 10.1128/JVI.74.5.2186-2192.2000 Boesen, 2005, Lassa fever virus peptides predicted by computational analysis induce epitope-specific cytotoxic-T-lymphocyte responses in HLA-A2.1 transgenic mice, Clin Diagn Lab Immunol, 12, 1223, 10.1128/CDLI.12.10.1223-1230.2005 Botten, 2006, Identification of protective Lassa virus epitopes that are restricted by HLA-A2, J Virol, 80, 8351, 10.1128/JVI.00896-06 Liu, 2006, Peptide vaccination of mice immune to LCMV or vaccinia virus causes serious CD8+ T cell-mediated TNF-dependent immunopathology, J Clin Invest, 116, 465, 10.1172/JCI25608 Ter Meulen, 1996, Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea, Am J Trop Med Hyg, 55, 661, 10.4269/ajtmh.1996.55.661 Maiztegui, 1972, Activity of lymphocytic choriomeningitis virus (LCM) in the endemic area of Argentine hemorrhagic fever (AHF). Part I. Serological studies in rodents captured in the City of Pergamino, Medicina (B Aires), 32, 131 Daddario-DiCaprio, 2006, Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment, Lancet, 367, 1399, 10.1016/S0140-6736(06)68546-2 Baize, 2006, Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages, Microbes Infect, 8, 1194, 10.1016/j.micinf.2006.02.002 Baize, 2004, Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells, J Immunol, 172, 2861, 10.4049/jimmunol.172.5.2861 Lukashevich, 1999, Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: different effects on IL-8 and TNF-a gene expression, J Med Virol, 59, 552, 10.1002/(SICI)1096-9071(199912)59:4<552::AID-JMV21>3.0.CO;2-A Pannetier, 2004, Human macrophages, but not dendritic cells, are activated and produce alpha/beta interferons in response to Mopeia virus infection, J Virol, 78, 10516, 10.1128/JVI.78.19.10516-10524.2004 Hotchin, 1962, The biology of lymphocytic choriomeningitis virus: virus induced immune disease, Coldspring Harbor Symp Quant Biol, 27, 479, 10.1101/SQB.1962.027.001.046 Binder, 1997, Virus-induced transient bone marrow aplasia: Major role of interferon-alpha/beta during acute infection with the noncytopathic lymphocytic choriomeningitis virus, J Exp Med, 185, 517, 10.1084/jem.185.3.517 Diebold, 2003, Viral infection switches non-plasmacytoid dendritic cells into high interferon producers, Nature, 424, 324, 10.1038/nature01783 Moskophidis, 1994, Resistance of lymphocytic choriomeningitis virus to alpha/beta interferon and to gamma interferon, J Virol, 68, 1951, 10.1128/JVI.68.3.1951-1955.1994 Borrow, 1995, Destruction of virus-infected dendritic cells results in generalized immune suppression, J Virol, 69, 1059, 10.1128/JVI.69.2.1059-1070.1995 Zarozinkski, 2000, Bystander sensitization to activation-induced cell death as a mechanism of virus-induced immune suppression, J Virol, 74, 3650, 10.1128/JVI.74.8.3650-3658.2000 Mahanty, 2003, Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection, Virology, 312, 415, 10.1016/S0042-6822(03)00233-2 Bray, 2001, The role of the type I interferon response in the resistance of mice to filovirus infection, J Gen Virol, 82, 1365, 10.1099/0022-1317-82-6-1365 Pedras-Vasconcelos, 2006, CpG ODN protect newborn mice from a lethal challenge with the neurotropic Tacaribe Arenavirus, J Immunol, 176, 4940, 10.4049/jimmunol.176.8.4940